中国实用儿科杂志

中国实用儿科杂志 ›› 2026, Vol. 41 ›› Issue (2): 125-128.DOI: 10.19538/j.ek2026020608

• 专题笔谈 • 上一篇    下一篇

儿童中重度特应性皮炎系统治疗进展

  

  1. 中国医科大学附属第一医院，辽宁  沈阳  110001
  • 出版日期:2026-02-06 发布日期:2026-03-13
  • 通讯作者: 肖汀，电子信箱：cmuxt@126.com

Advances in systemic treatment for pediatric moderate-tosevere atopic dermatitis

  1. The First Hospital of China Medical University，Shenyang  110001，China
  • Online:2026-02-06 Published:2026-03-13

摘要： 特应性皮炎（atopic dermatitis，AD）是一种好发于儿童的慢性、复发性、瘙痒性、2型炎症性皮肤病，主要特征为湿疹样皮损、剧烈瘙痒，常伴有血清 IgE 升高，常合并食物过敏、哮喘和变应性鼻炎。儿童轻度 AD 常外用皮质激素和（或）钙调磷酸酶抑制剂控制，但儿童中重度 AD 常需要系统治疗。目前中重度 AD 的一线系统治疗包括生物制剂、环孢素、糖皮质激素，二线治疗包括 JAK 抑制剂和其他传统免疫抑制剂。该文重点介绍这些系统药物治疗的最新进展。

关键词:

Abstract: Atopic dermatitis（AD）is a chronic，recurrent，pruritic，type 2 inflammatory skin disease that commonly affects children.AD is primarily characterized by eczematous skin lesions，intense itching and elevated serum IgE levels， and is often associated with food allergy，asthma and allergic rhinitis.Pediatric cases of mild AD are often controlled by topical corticosteroids and/or calcineurin inhibitors.However，pediatric patients with moderate-to-severe AD usually require systemic therapies.Currently，first-line systemic treatments for moderate-to-severe AD include biologics，cyclosporine and corticosteroids， while second-line treatment mainly consists of JAK inhibitors and other traditional immunosuppressants.This article focuses on the latest advances in the systemic pharmacological therapies.

Key words: